Verbatim response from ChatGPT
Short answer
- Many people on the newer GLP‑1 / GIP–GLP‑1 drugs (semaglutide, tirzepatide) lose meaningful weight within weeks and substantial weight over months. Typical trial results and clinical experience are roughly 10–20% body‑weight loss within 6–12 months for the higher‑dose agents, with wide individual variation.
- Sustainability: weight is often maintained while the medicine is continued plus lifestyle changes. Stopping the drug commonly leads to partial or full weight regain over months unless intensive behavior/meal changes continue.
How fast you can expect to lose weight
- Early phase (0–3 months): many people lose a few kilograms (several percent of body weight) quickly as appetite drops and intake falls.
- Medium term (3–6 months): typical additional loss; many people reach ~5–15% total weight loss depending on drug, dose, and adherence.
- Longer term (6–12 months+): clinical trials of the higher‑dose agents show average losses in the teens of percent body weight (semaglutide ~12–15% in STEP trials; tirzepatide in SURMOUNT trials produced even larger average reductions, sometimes >20% at higher doses). Individual results vary — some lose more, some less.
What changes the speed and amount
- Which drug and dose: tirzepatide (brand names Mounjaro for diabetes; Zepbound for weight management) generally produced larger average losses in trials than semaglutide (Wegovy is the semaglutide product approved for weight management; Ozempic is semaglutide for diabetes often used off‑label).
- Baseline weight/composition, metabolism, genetics.
- How well you tolerate the med (nausea can limit dose escalation), adherence, and whether you combine it with diet, physical activity, and behavioral therapy.
- Other medical conditions and medications.
Sustainability — what to expect long term
- Continued treatment + lifestyle support: many people maintain most of the loss. GLP‑1s change appetite and food reward, so the drug supports lower intake.
- Stopping the drug: trials and real‑world data show a substantial risk of regaining weight after stopping unless intensive lifestyle measures are sustained. In other words, for many people long‑term or intermittent treatment is needed to keep the weight off.
- Best long‑term outcomes come from combining medication with structured lifestyle change, frequent follow‑up, and addressing behavioral and medical contributors to weight.
Safety and practical points
- These drugs are prescription medicines and need supervision by a clinician. Common side effects include nausea, vomiting, constipation, and rarely pancreatitis or gallbladder problems. There are specific warnings (e.g., personal/family history of medullary thyroid cancer is a contraindication).
- Expect dose titration over weeks to months to reach an effective/ tolerated dose. Cost and insurance coverage vary; newer agents can be expensive.
- Work with an obesity medicine specialist or your primary care provider to set realistic targets and monitor labs and side effects.
Brands to know (brief)
- Wegovy (semaglutide 2.4 mg) — FDA‑approved for chronic weight management; strong trial data showing substantial average weight loss.
- Zepbound (tirzepatide) — FDA‑approved for weight management (and tirzepatide is available as Mounjaro for diabetes); trials showed larger average weight loss than semaglutide in head‑to‑head comparisons.
- Ozempic (semaglutide) and Mounjaro (tirzepatide) — approved for diabetes; sometimes used off‑label for weight loss but the approved weight‑management products/doses differ.
If you want a more specific estimate Tell me: current weight, height, which medication (or whether you’re planning to start one), and any major medical issues. I can give a personalized ballpark timeline and practical next steps.